U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Go back to U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations| (NYSE: TAK) | Delayed: 18.91 -0.14 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.05 | 52 Week High | $0.55 | |||
| Open | $18.80 | 52 Week Low | $0.55 | |||
| Day High | $19.01 | P/E | N/A | |||
| Day Low | $18.80 | EPS | $-0.20 | |||
| Volume | 2,960,710 | |||||
